The acquisition of surgical instrumentation, laparoscopic instrumentation, and sterilization container assets from Becton, Dickinson and Company (BD) for $539.8 million expands product offerings in the Healthcare segment.

The company announced its plan to sell its Dental segment for $787.5 million, representing a strategic shift that has (or will have) a major effect on the entity's operations and financial results.

The company adopted a restructuring plan that includes a strategic shift in the Healthcare surgical business in Europe, product rationalizations and facility consolidations, with the goal of improving profitability and efficiency.

The company continues to incorporate Lean concepts and practices to more efficiently operate its business, including in-sourcing. However, there is no guarantee that these activities will produce the full efficiencies and cost reduction benefits expected.

The employee turnover rate was 15% for both fiscal 2024 and 2023, and the company is continuously working towards a goal of achieving a rate of 10% or less, excluding retirements and reductions in force.

STERIS has an Executive Cybersecurity Steering Committee responsible for providing governance, risk and compliance oversight for STERIS's incident response program, providing guidance and support for cybersecurity non-technical initiatives, and for verifying that appropriate actions are taken following an incident occurrence.

Ongoing geopolitical instability, including as a result of the Russia-Ukraine and Israel-Hamas military conflicts, has negatively impacted, and could in the future negatively impact, the global and U.S. economies.

Numerous and evolving cybersecurity threats continue to pose potential risks to the security of our IT systems, networks and services, as well as the confidentiality, availability and integrity of our data.

The company is subject to extensive regulatory requirements and must receive and maintain regulatory clearance or approval for many products and operations. Failure to receive or maintain, or delays in receiving, clearance or approvals may negatively impact our revenues, profitability, financial condition, or value.

The markets in which we operate are highly competitive and generally highly regulated. Competition is intense in all of our business segments and includes many large and small competitors.

Consolidations among healthcare and pharmaceutical Customers may result in a loss of Customers or more significant pricing pressures.

The company believes that its long-term competitive position depends on its success in discovering, developing, and marketing innovative, cost-effective products and services.

Supply chain disruption might increase our production costs, limit our production capabilities or curtail our operations.

Our Continuous Improvement objectives include efforts to improve energy and water efficiency and reduce or eliminate certain chemicals used in, and wastes generated from, our operations thereby reducing the impact of our operations on the environment.

If our continuing efforts to create a Lean business and in-source production to reduce costs are not successful, our profitability may be hurt or our business otherwise might be adversely affected.

The company devotes significant resources to research and development efforts, and we believe STERIS is positioned as a global competitor in the search for technological innovations.

During fiscal 2024, our investments in research and development have continued to be focused on, but were not limited to, enhancing capabilities of sterile processing combination technologies, procedural products and accessories, and devices and support accessories used in gastrointestinal endoscopy procedures.

There can be no assurance that we will develop significant new products or services, or that the new products or services we provide or develop in the future will be more commercially successful than those provided or developed by our competitors.

We intend to use our existing cash and cash equivalent balances and cash generated from operations to fund capital expenditures and meet our other liquidity needs.

On May 3, 2023 our Board of Directors terminated the previous share repurchase program then in effect and authorized a new share repurchase program for the purchase of up to $500.0 million (net of taxes, fees and commissions), which has no specified expiration date.

During the year, we increased our quarterly dividend for the eighteenth consecutive year to $0.52.

Our Code of Business Conduct sets the standard for legal and ethical behavior, addressing topics such as bribery and corruption, supply chain transparency, proper behavior in the workplace, and avoiding conflicts of interest.

The company is subject to various laws and governmental regulations concerning environmental matters and employee safety and health in Ireland, the United States and other countries.

The company is committed to upholding human rights in all our operations globally and respect human rights as recognized by the principles of the United Nations Global Compact.

Much of the growth in these industries is driven by the aging of the population throughout the world, as an increasing number of individuals are entering their prime healthcare consumption years.

The effects of geopolitical instability, including as a result of the Russia-Ukraine and Israel-Hamas military conflicts, may adversely affect us and create significant risks and uncertainties for our business, with the ultimate impact dependent on future developments, which are highly uncertain and unpredictable.

Various additional healthcare reform proposals have emerged at the federal and state level, and we are unable to predict which, if any, of those proposals will be enacted.